Royalty Table

Royalties from other partnered products not listed are either single or double digit royalties as described under collaborative research and development programs in the current 10-K. Not all royalties are disclosed due to confidentiality requirements.

 

 

Eltrombopag (PROMACTA®)(1)(2)		4.7%  6.6%  7.5%  9.4%  9.3%	Less than $100M annual sales Sales in range of $100M - $200M  Sales in range of $200M - $400M  Sales greater than $400M  Sales greater than $1.5B
GSK-5921(2)		14.5%	All sales (6.5% for first year sales)
Carfilzomib (KYPROLIS®)(1)		1.5%  2.0%  2.5%  3.0%	Sales up to and including $250M  Sales in range of $251M - $500M  Sales in range of $501M - $750M  Sales greater than $750M
AVINZA® (1)		5%	If sales are less than $200M annually  Higher royalties paid if sales exceed $200M
Bazedoxifene (VIVIANT™)(1) BZA/CE		0.5%  1.5%  2.5%	Less than $400M annual sales  Sales in range of $400M - $1.0B annually  Sales greater than $1B annually
RE-021		9%	All sales

 

(1)	Currently receiving royalty payments
(2)	Net of payments due to The Rockefeller University.